<DOC>
	<DOCNO>NCT00660452</DOCNO>
	<brief_summary>A phase III study ass efficacy safety sublingual immunotherapy STALORAL dust mite solution compare placebo reduction asthma symptom .</brief_summary>
	<brief_title>A Phase III Study Assess Efficacy Safety STALORAL® 300 IR Sublingual Immunotherapy ( SLIT ) Asthmatic Patients Allergic House-dust Mites</brief_title>
	<detailed_description />
	<criteria>1 . Male female outpatient age 16 50 year ( inclusive ) . 2 . House dust miteinduced allergic asthma without perennial allergic rhinitis least 1 year . 3 . Sensitised D. pteronyssinus D.farinae ( positive skin prick test ( SPT ) wheal diameter ≥ 4 mm specific IgE level ≥ 0.70 kU/L 4 . Patients treat inhaled corticosteroid ( ICS ) screen visit dose ≥ 200 µg &lt; 1,000 µg equivalent budesonide/day . 1 . Mild intermittent asthma need treated β2agonist ( GINA level 1 ) . 2 . Severe asthma need treat inhaled corticosteroid dose ≥ 1,000 µg/day equivalent budesonide . 3 . FEV1 &lt; 70 % predict value Visit 1 . 4 . Cosensitisation inhalant allergens dust mite lead clinically relevant allergic asthma proven positive skin prick test wheal diameter ≥ 4 mm serum specific IgE ≥ 0.70 KU/L . 5 . Patients past current disease , judge investigator , may affect patient 's participation outcome study . These disease include , limited , past current cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , immunological disease endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Allergy</keyword>
	<keyword>SLIT</keyword>
	<keyword>Asthma</keyword>
	<keyword>House Dust Mites</keyword>
</DOC>